These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Future directions in the treatment of cholangiocarcinoma. Zhu AX Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434 [TBL] [Abstract][Full Text] [Related]
14. lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma. Qiu G; Ma D; Li F; Sun D; Zeng Z Int J Oncol; 2019 Jul; 55(1):45-58. PubMed ID: 31059014 [TBL] [Abstract][Full Text] [Related]
16. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. Raggi C; Invernizzi P; Andersen JB J Hepatol; 2015 Jan; 62(1):198-207. PubMed ID: 25220250 [TBL] [Abstract][Full Text] [Related]
17. Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma. Lin KY; Ye H; Han BW; Wang WT; Wei PP; He B; Li XJ; Chen YQ Oncogene; 2016 Jun; 35(26):3376-86. PubMed ID: 26455324 [TBL] [Abstract][Full Text] [Related]
19. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway. Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203 [TBL] [Abstract][Full Text] [Related]
20. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review). Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]